Role of aripiprazole in the management of behavioural and psychological symptoms of dementia: a narrative review.
Baldomero Álvarez-FernándezMaria Rosa Bernal-LopezRicardo Gómez-HuelgasPublished in: Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society (2021)
Behavioural and psychological symptoms of dementia affect in a great way quality of life of both patients and their caregivers, which increases the risk of patient institutionalisation when such symptoms are poorly controlled. One of the drugs that are used for controlling behavioural and psychological symptoms of dementia (BPSD) is aripiprazole. This narrative review aims to solve three basic questions. Is aripiprazole useful for the management of these symptoms? Does aripiprazole play a substantial role regarding safety and efficacy, compared with the other pharmacological options available for the same purpose? Has aripiprazole gained importance in treatment regimens of these symptoms, in current clinical practice? We conclude that aripiprazole is effective to manage BPSD. Moreover, it has shown a good safety profile compared with other antipsychotics in advanced disease and frail patients. Thus, aripiprazole has gained importance in current management algorithms for dementia patients mainly due to its efficacy regarding rapid control of agitation and aggressiveness.
Keyphrases
- end stage renal disease
- ejection fraction
- mild cognitive impairment
- newly diagnosed
- chronic kidney disease
- sleep quality
- prognostic factors
- cognitive impairment
- clinical practice
- palliative care
- depressive symptoms
- case report
- drug induced
- smoking cessation
- quantum dots
- combination therapy
- loop mediated isothermal amplification